Results 171 to 180 of about 25,164 (313)

The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes [PDF]

, 2004
H.K. Crewe, M.S. Lennard, G.T. Tucker, Fleas Woods, R.E. Haddock   +4 more
openalex   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Dopamine and serotonin neurotransmissions exert complementary control over primate approach and avoidance. [PDF]

Transl Psychiatry
Gauthier L, Drui G, Debatisse J, Saga Y, Millot M, Martinez E, Météreau E, Portier K, Tobler PN, Tremblay L, Pasquereau B.   +10 more
europepmc   +1 more source

Designing rapid onset selective serotonin re-uptake inhibitors. 2: Structure–activity relationships of substituted (aryl)benzylamines

, 2008
Donald S. Middleton, Mark D. Andrews, Paul A. Glossop, Geoffrey E. Gymer, David Hepworth, Alan S. Jessiman, Patrick S. Johnson, Malcolm MacKenny, Michael J. Pitcher, Tony Rooker, Alan Stobie, Kim Tang, Paul Morgan   +12 more
openalex   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Evaluating the rational use of antidepressant in older patients: a comprehensive analysis of its association with cognitive impairment. [PDF]

Front Psychiatry
Gil-Peinado M, Pardo J, García-Zamora M, Adsuar-Meseguer GM, Sendra-Lillo J, Moreno L.   +5 more
europepmc   +1 more source

Thioether Metabolites of 3,4-Methylenedioxyamphetamine and 3,4-Methylenedioxymethamphetamine Inhibit Human Serotonin Transporter (hSERT) Function and Simultaneously Stimulate Dopamine Uptake into hSERT-Expressing SK-N-MC Cells

, 2004
Douglas C. Jones, Serrine S. Lau, Terrence J. Monks   +2 more
openalex   +1 more source

Selective serotonin re-uptake inhibitors and the risk of violent suicide: a nationwide postmortem study [PDF]

, 2018
Jonas Forsman, Thomas Masterman, Johan Ahlner, Göran Isacsson, Anna Karin Hedström   +4 more
openalex   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Structural basis of vilazodone dual binding mode to the serotonin transporter. [PDF]

Nat Commun
Kalenderoglou IE, Nygaard A, Vogt CD, Turaev A, Pape T, Adams NBP, Newman AH, Loland CJ.   +7 more
europepmc   +1 more source